Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com -- Tivic Health Systems Inc (NASDAQ:TIVC) stock rose 5% after the company announced that shareholders approved key proposals needed to execute its strategic transformation at its annual meeting on June 30, 2025.
The immunotherapeutics company received shareholder approval for the issuance of equity as payment for its worldwide exclusive license agreement for Entolimod and Entolasta. These therapies are being developed for uses in acute radiation syndrome, neutropenia, and other oncology and hematology indications. Shareholders also approved equity issuance related to previously announced financing arrangements, both approvals being required under Nasdaq listing rules.
"We have established a strong foundation for Tivic’s expansion into biopharmaceutical markets -- starting with commercialization of Entolimod for two large-market indications," stated Tivic CEO Jennifer Ernst in the announcement.
The company also revealed leadership changes, with Lisa Wolf assuming the permanent role of Chief Financial Officer after serving as interim CFO for nine months. Additionally, Blake Gurfein is stepping down as Chief Scientific Officer after eight years to take on a consultant role, where he will continue supporting the company’s Vagus Nerve Stimulation program.
Tivic Health, which describes itself as a diversified immunotherapeutics company, has previously commercialized ClearUP, an FDA-approved product, and is now expanding its portfolio with these newly licensed therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.